Skip to content

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

A Phase 2 Proof-of-concept Study of Gevokizumab in Subjects With Inflammatory Erosive Osteoarthritis of the Hand

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01882491
Enrollment
91
Registered
2013-06-20
Start date
2013-05-31
Completion date
2014-02-28
Last updated
2014-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Erosive Osteoarthritis, Osteoarthritis, Osteoarthritis of the Hand

Brief summary

The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of inflammatory erosive osteoarthritis of the hand.

Interventions

DRUGPlacebo

Solution for subcutaneous injection

Solution for subcutaneous injection

Sponsors

XOMA (US) LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of hand osteoarthritis * Joint tenderness and/or redness * At least one erosion by X-ray (as determined by the central reader) * Contraceptive measures adequate to prevent pregnancy during the study

Exclusion criteria

* History of inflammatory disease other than hand EOA including: secondary post-traumatic OA; rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia * History of gout, pseudogout, or hemochromatosis * History of allergic or anaphylactic reactions to monoclonal antibodies * History of recurrent or chronic systemic infections * Known allergy to acetaminophen * Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding Other protocol-defined inclusion/

Design outcomes

Primary

MeasureTime frameDescription
Percent change from baseline in AUSCAN pain score at Day 84Baseline and Day 84The Australian/Canadian (AUSCAN) Osteoarthritis Hand Index is a self-report assessment of pain, stiffness, and function in patients with hand osteoarthritis.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026